Furthermore, M2 TAMs enhance immune evasion by recruiting Tregs and other suppressive immune cells, while also facilitating the expression of immune checkpoint molecules like PD-L1 on tumor and immune cells, thereby undermining the efficacy of immune checkpoint inhibitors and compromising immunotherapy outcomes [11,12]. Here, CD274 is linked to neoplasm.